Viatris Q3 2024: Revenue $3.8B, GAAP EPS $0.08, Adjusted EPS $0.75, Repaid $1.9B Debt

Viatris Inc

2024-Q3 EPS reported -$0.10 revenue$11,211,200,000

Total revenues $3.8B, operational revenue growth ~3% on divestiture-adjusted basis; new product revenues $133M.
GAAP net earnings $95M ($0.08 diluted EPS); adjusted EBITDA ~$1.3B (+4% divestiture-adjusted); adjusted EPS $0.75 (+6%).
Repaid ~$1.9B debt including make-whole call; expects to reach ~3.0x gross leverage target by year-end.
Entered exclusive licensing agreement with Lexicon for sotagliflozin outside U.S. and Europe.
Reaffirms 2024 full-year outlook: ~2% revenue growth on divestiture-adjusted operational basis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.